Natalizumab

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3661 publications

Rasmussen Encephalitis, Case Report And Review Of The Literature

Rasmussen Encephalitis, Case Report And Review Of The Literature

Journal: Le Mali medical
Published: September 01, 2026

Fatal cerebral toxoplasmosis in a patient with multiple sclerosis treated with natalizumab.

Fatal cerebral toxoplasmosis in a patient with multiple sclerosis treated with natalizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 18, 2026

Opportunistic infections in people treated with natalizumab - beyond PML.

Opportunistic infections in people treated with natalizumab - beyond PML.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 18, 2026

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Journal: Health technology assessment (Winchester, England)
Published: August 11, 2026

The Art of Sequencing Disease-Modifying Therapies in Multiple Sclerosis.

The Art of Sequencing Disease-Modifying Therapies in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: July 16, 2026

Circadian screening of neutrophils identifies therapeutic targets in multiple sclerosis.

Circadian screening of neutrophils identifies therapeutic targets in multiple sclerosis.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 08, 2026

Absolute and Relative Quantification of Glycation on Biotherapeutic IgGs Using Heavy Isotope-Labeled Proteins.

Absolute and Relative Quantification of Glycation on Biotherapeutic IgGs Using Heavy Isotope-Labeled Proteins.

Journal: Journal of biomolecular techniques : JBT
Published: June 25, 2026

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

Journal: Journal of medical economics
Published: June 24, 2026

Serum neurofilament light chain in paediatric patients treated with natalizumab for highly active multiple sclerosis.

Serum neurofilament light chain in paediatric patients treated with natalizumab for highly active multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: June 23, 2026

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

Journal: The Cochrane database of systematic reviews
Published: June 23, 2026

Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis.

Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis.

Journal: Journal of medical economics
Published: June 21, 2026

Visual and Neuro-Ophthalmic Manifestations of John Cunningham (JC) Virus-Related Natalizumab-Associated Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Systematic Review.

Visual and Neuro-Ophthalmic Manifestations of John Cunningham (JC) Virus-Related Natalizumab-Associated Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Systematic Review.

Journal: Cureus
Published: June 12, 2026
Showing 1-12 of 3,661

Last Updated: 09/26/2026